Integrated CRO ChemDiv is a long-standing, full-spectrum Target-to-Market CRO with 25 years of experience, global reach, and integrated discovery to clinical proof of concept, presenting a single-source partner for end-to-end drug development to accelerate timelines.

Expansion Momentum Recent news highlights ongoing expansion in capabilities and partnerships, including launching Chemistry, Manufacturing and Controls services, extending discovery and early development collaborations, and board-level business development hires, signaling appetite for deeper client engagement and larger scope projects.

Strategic Partnerships Active collaborations with universities and biotech companies (UTMB, Mondego Bio) indicate a proven pathway for co-investment models and access to novel platforms, suggesting opportunities to co-develop under-exploited assets or joint ventures with pharma/biotech clients.

Portfolio Depth A diversified project portfolio across CNS, oncology, inflammation, metabolic and infectious diseases with proprietary chemistry and discovery platforms, offering multiple entry points for pharma partners seeking specialized screening libraries and rapid hit-to-candidate progression.

Financial Scale Revenue in the multi-billion range with a sizable, multinational, mid-sized CRO profile positions ChemDiv as a capable partner for large strategic out-sourcing deals, renewals of ongoing programs, and expansion of existing programs into R&D operations.